Valneva SE announced that the UK Commission on Human Medicines updated recommendations for its chikungunya vaccine IXCHIQ®, restricting use in individuals over 60 and those with specified health conditions. The MHRA confirmed the benefit-risk profile remains favorable for individuals aged 18 to 59 at risk of infection.
Key takeaways
The UK Commission on Human Medicines updated recommendations for Valneva's single-dose chikungunya vaccine, IXCHIQ®.
New restrictions include individuals over 60 years of age and people with specified health conditions.
The MHRA confirmed the benefit-risk profile remains favorable for individuals aged 18 to 59 who do not have contraindicated underlying medical conditions.
The update follows MHRA's temporary suspension on the use of IXCHIQ® in older individuals based on reports of serious adverse events during a vaccination campaign on La Reunion.
Valneva stated it will continue monitoring post-marketing safety data and work with authorities to potentially update recommendations if justified.